Effects of a biologic agent in a patient with rheumatoid arthritis after treatment for methotrexate-associated B-cell lymphoma: A case report

BMC Research Notes

Volumn 7, Issue 1, 2014, Pages

  Kuroda, Takeshi ^a,b   Sato, Hiroe ^b   Nakatsue, Takeshi ^b   Wada, Yoko ^b   Murakami, Shuichi ^b   Nakano, Masaaki ^a   Narita, Ichiei ^b  

^a NIIGATA UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Biologics; Lymphoma; Rheumatoid arthritis

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTOR; METHOTREXATE; MONOCLONAL ANTIBODY; RITUXIMAB; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ARTHRITIS, RHEUMATOID; B LYMPHOCYTE; CASE REPORT; CHEMICALLY INDUCED; DRUG EFFECTS; HUMAN; IMMUNOLOGY; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PATHOLOGY;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; LYMPHOMA, B-CELL; MALE; METHOTREXATE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 84899472809     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-7-229     Document Type: Article

References (43)

1. Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Pincus T, Ferraccioli G, Sokka T, Larsen A, Rau R, Kushner I, Wolfe F, Rheumatology (Oxford) 2002 41 1346 1356 10.1093/rheumatology/41.12.1346 12468813
2. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Krause D, Scleusser B, Herborn G, Rau R, Arthritis Rheum 2000 43 14 21 10.1002/1529-0131(200001)43:1<14::AID- ANR3>3.0.CO;2-7 10643695
3. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four cases reports and a review of the literature. Searles G, McKendry RJR, J Rheumatol 1987 14 1164 1171 3325643
4. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Carson CW, Cannon GW, Egger MJ, Ward JR, Clegg DO, Semin Arthritis Rheum 1987 16 186 195 10.1016/0049-0172(87)90021-7 3823910
5. Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate. Carroll GJ, Thomas R, Phatouros CC, Atchison MH, Lesile AL, Cook NJ, D'Souza I, J Rheumatol 1994 21 51 54 8151587
6. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. Ohosone Y, Okano Y, Kameda H, Fujii T, Hama N, Hirakata M, Mimori T, Akizuki M, Ikeda Y, J Rheumatol 1997 24 2299 2303 9415631
7. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Kremer JM, Alarcon GS, Weinblatt ME, Kaymakcian MV, Macaluso M, Cannon GW, Palmer WR, Sundy JS, St. Clair EW, Alexander RW, Smith GJ, Axiotis CA, Arthritis Rheum 1997 40 1829 1837 10.1002/art.1780401016 9336418
8. Methotrexate pulmonary toxicity. Cannon GW, Rheum Dis Clin North Am 1997 23 917 937 10.1016/S0889-857X(05)70366-5 9361161
9. Methotraxate pneumonitis: review of the literature and histopathological findings in nine patients. Imokawa S, Colby TV, Leslie KO, Helmers RA, Eur Respir J 2000 15 373 381 10.1034/j.1399-3003.2000.15b25.x 10706507
10. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Gutierrez-Urena S, Molina JF, García CO, Cuéllar ML, Espinoza LR, Arthritis Rheum 1996 39 272 276 10.1002/art.1780390214 8849378
11. Clinical characteristics related to methotrexate-induced pancytopenia. Ohosone Y, Okano Y, Kameda H, Hama N, Mimori T, Akizuki M, Ikeda Y, Clin Rheumatol 1997 16 321 323 10.1007/BF02238974 9184276
12. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Georgescu L, Quinn GC, Schwartzman S, Paget SA, Semin Arthritis Rheum 1997 26 794 804 10.1016/S0049-0172(97)80023-6 9213378
13. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. Feng W-H, Cohen JI, Fischer S, Li L, Sneller M, Goldbach-Mansky R, Raab-Traub N, Delecluse HJ, Kenney SC, J Natl Cancer Inst 2004 96 1691 1702 10.1093/jnci/djh313 15547182
14. Spontaneous remission of low-grade B-cell non-Hodgkin's lymphoma following withdrawal of methotrexate in a patient with rheumatoid arthritis: case report and review of the literature. Baird RD, van Zyl-Smit RN, Dilke T, Scott SE, Rassam SMB, Br J Haematol 2002 118 567 568 10.1046/j.1365-2141.2002. 03619.x 12139747
15. Methotrexate-induced pulmonary lymphoma. Ebeo CT, Girish MR, Byrd RP, Roy TM, Mehta JB, Chest 2003 123 2150 2153 10.1378/chest.123.6.2150 12796204
16. A population based, case control study of non-Hodgkin's lymphoma in patients with rheumatoid arthritis. Kamel OW, Holly EA, van de Rijn M, Lele C, Sah A, J Rheumatol 1999 26 1676 1680 10451061
17. Non-Hodgkin's lymphoma in patients with rheumatoid arthritis treated with low dose methotrexate. Usman AR, Yunus MB, J Rheumatol 1996 23 1095 1097 8782146
18. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J, Investigators of the Club Rhumatismes et Inflammation, Blood 2002 99 3909 3915 10.1182/blood.V99.11.3909 12010788
19. Excess risk of lung cancer in patients with rheumatoid arthritis. Kauppi M, Pukkala E, Isomäki H, J Rheumatol 1996 23 1484 1485 8856639
20. Rheumatoid arthritis and cancer risk. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Møller H, Olsen JH, Eur J Cancer 1996 32 1753 1757 10.1016/0959-8049(96)00210-9
21. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Klareskog L, Ann Rheum Dis 2005 64 1421 1426 10.1136/ard.2004.033993 15829572
22. Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort. Katusic S, Beard CM, Kurland LT, Weis JW, Bergstralh E, Am J Med 1985 78 50 55 10.1016/0002-9343(85)90246-3 3970041
23. Rheumatoid arthritis and the risk of malignancy. Cibere J, Sibley J, Haga M, Arthritis Rheum 1997 40 1580 1586 10.1002/art.1780400906 9324011
24. Risk of malignancy among patients with rheumatic conditions. Thomas E, Brewster DH, Black RJ, Macfarlane GJ, Int J Cancer 2000 88 497 502 10.1002/1097-0215(20001101)88:3<497::AID-IJC27>3.0.CO;2-J 11054684
25. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first degree relatives. Ekstorm K, Hjalgrim H, Brandt L, Baecklund E, Klareskog L, Ekbom A, Askling J, Arthritis Rheum 2003 48 963 970 10.1002/art.10939 12687538
26. The incidence of cancer among Japanese patients with rheumatoid arthritis in 2003 obtained by using Ninja. Chiba N, Mod Rheumatol 2006 16 Suppl 202
27. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Wolfe F, Michaud K, Arthritis Rheum 2004 50 1740 1751 10.1002/art.20311 15188349
28. Lymphomatoid granulomatosis and diffuse alveolar damage associated with methotrexate therapy in a patient with rheumatoid arthritis. Kameda H, Okuyama A, Tamaru J, Itoyama S, Iizuka A, Takeuchi T, Clin Rheumatol 2007 26 1585 1589 10.1007/s10067-006-0480-2 17200802
29. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. Kamel OW, van de Rijn M, Weiss LM, Del Zoppo GJ, Hench PK, Robbins BA, Montgomery PG, Warnke RA, Dorfman RF, N Engl J Med 1993 328 1317 1321 10.1056/NEJM199305063281806 8385742
30. Methotrexate-related lymphomatoid granulomatosis: a case report of spontaneous regression of large tumours in multiple organs after cessation of methotrexate therapy in rheumatoid arthritis. Shimada K, Matsui T, Kawakami M, Nakayama H, Ozawa Y, Mitomi H, Tohma S, Scand J Rheumatol 2007 36 64 67 10.1080/03009740600902403 17454938
31. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. Kamel OW, Cooper DL, Howe G, Lacy J, Tallini G, Crouch J, Schultz M, Murren J, J Clin Oncol 1996 14 1943 1949 8656264
32. Safety, efficacy and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: follow-up after a mean of 13.3 years. Kremer JM, Arthritis Rheum 1997 40 984 985 10.1002/art.1780400533 9153566
33. Long-term prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. Weinblatt ME, Maier AL, Fraser PA, Coblyn JS, J Rheumatol 1998 25 238 242 9489813
34. Association of chronic inflammation not its treatment, with increased lymphoma risk in rheumatoid arthritis. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, Catrina AI, Rosenquist R, Feltelius N, Sundström C, Klareskog L, Arthritis Rheum 2006 54 692 701 10.1002/art.21675 16508929
35. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L, Br Med J 1998 317 180 181
36. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Wolfe F, Michaud K, Arthritis Rheum 2007 56 1433 1439 10.1002/art.22579 17469100
37. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Geborek P, Bladström A, Turesson C, Gulfe A, Petersson IF, Saxne T, Olsson H, Jacobsson LT, Ann Rheum Dis 2005 64 699 703 10.1136/ard.2004.030528 15695534
38. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V, JAMA 2006 295 2275 2285 10.1001/jama.295.19.2275 16705109
39. Effect of tumor necrosis factor alpha and infliximab on apoptosis of B lymphocytes infected or not with Epstein-Barr virus. Baran-Marszak F, Laguillier C, Youlyouz I, Feuillard J, Mariette X, Fagard R, Raphaël M, Cytokine 2006 33 337 345 10.1016/j.cyto.2006.03.005 16713282
40. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, To K, Harashima S, Hatta N, Harada M, Arthritis Rheum 2008 58 1248 1257 10.1002/art.23447 18438840
41. In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. Roll P, Muhammad K, Schumann M, Kleinert S, Einsele H, Dörner T, Tony HP, Arthritis Rheum 2011 63 1255 1264 10.1002/art.30242 21305508
42. Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. Davis PM, Abraham R, Xu L, Nadler SG, Suchard SJ, J Rheumatol 2007 34 2204 2210 17787038
43. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, Brown D, Robinson M, Bourne T, Inflamm Bowel Dis 2007 13 1323 1332 10.1002/ibd.20225 17636564